Tevogen Bio (NASDAQ:TVGN) Shares Up 6.2% – Should You Buy?

Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shot up 6.2% on Friday . The stock traded as high as $10.95 and last traded at $10.47. 100,552 shares changed hands during trading, an increase of 161% from the average session volume of 38,592 shares. The stock had previously closed at $9.86.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TVGN. Wall Street Zen downgraded Tevogen Bio to a “strong sell” rating in a research note on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Monday, April 20th. Finally, D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $100.00.

Tevogen Bio Stock Performance

The company has a 50 day moving average price of $7.24 and a two-hundred day moving average price of $12.66. The firm has a market capitalization of $43.56 million, a price-to-earnings ratio of -2.27 and a beta of 0.14.

Tevogen Bio (NASDAQ:TVGN) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.61) EPS for the quarter, beating the consensus estimate of ($2.64) by $1.03.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC raised its stake in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the last quarter. Deutsche Bank AG raised its stake in Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.